Form 4: Avadel Director Sells All Shares in Alkermes Merger

Avadel Pharmaceuticals director Geoffrey Glass disposed of all his shares and options following the company's acquisition by Alkermes for $21 cash plus a CVR per share.

Summary

• Geoffrey Michael Glass, a director of Avadel Pharmaceuticals plc, reported the disposition of all his beneficial ownership in the company.
• This disposition occurred on February 12, 2026, as a result of Alkermes plc acquiring Avadel Pharmaceuticals plc through a scheme of arrangement.
• Each outstanding Avadel Ordinary Share was converted into $21.00 in cash and a non-transferable contingent value right (CVR) for a potential additional $1.50 per share, contingent on certain milestones.
• Restricted Stock Awards vested in full and were treated like other Ordinary Shares.
• All outstanding stock options were canceled and exchanged for a cash amount (Cash Consideration minus exercise price) and one CVR per share.
• Glass disposed of a total of 166,984 Ordinary Shares (22,005 directly, 69,075 indirectly via The Geoffrey Glass Trust, and 75,904 indirectly via Geoffrey M. Glass Revocable Trust U/T/D August 26, 2020).
• He also disposed of 221,000 stock options held indirectly via Geoffrey M. Glass Revocable Trust U/T/D August 26, 2020, with exercise prices ranging from $2.03 to $16.32.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event for Avadel shareholders, as it represents a completed acquisition providing immediate cash and potential future upside via a CVR, albeit with the inherent uncertainty of milestone achievement.

Positives

• Avadel Pharmaceuticals shareholders received a definitive cash payment of $21.00 per share.
• Shareholders also received a contingent value right (CVR) for a potential additional $1.50 per share, offering upside potential.
• All outstanding Restricted Stock Awards vested in full at the effective time of the merger.
• Stock options were cashed out, providing liquidity to option holders.

Negatives

• Avadel Pharmaceuticals plc ceased to be an independent publicly traded entity.
• The reporting person, Geoffrey Michael Glass, no longer holds any direct or indirect beneficial ownership in Avadel Pharmaceuticals plc.
• The additional $1.50 per share from the CVR is contingent and not guaranteed.

Risks

• The contingent value right (CVR) payment of $1.50 per share is dependent on the achievement of certain unspecified milestones and is therefore not guaranteed.

Future Outlook

The potential for an additional $1.50 per share payment through the contingent value right (CVR) remains, subject to the achievement of specific, undisclosed milestones.

Industry Context

StockSavvy.ai notes that this acquisition by Alkermes plc of Avadel Pharmaceuticals plc reflects a continuing trend of consolidation within the pharmaceutical and biotechnology sectors, where larger companies seek to expand their pipelines or market share through strategic M&A activities. Such transactions often involve a mix of upfront cash and contingent value rights to manage risk and reward based on future performance or regulatory milestones.

Comparison to Industry Standards

• This transaction structure, combining a fixed cash payment with a contingent value right (CVR), is a common approach in pharmaceutical M&A, particularly when the acquired company has assets with future value dependent on clinical or regulatory success.
• Similar CVR structures have been seen in deals like Bristol-Myers Squibb's acquisition of Celgene or Merck's acquisition of Acceleron Pharma, where CVRs were tied to specific drug approvals or sales milestones.
• The $21.00 cash consideration per share, plus a potential $1.50 CVR, provides a clear valuation for Avadel's equity at the time of the merger.

Corporate Governance

Related Party Transactions

• The disposition of shares and options held by "The Geoffrey Glass Trust" and "Geoffrey M. Glass Revocable Trust U/T/D August 26, 2020" are related party transactions, as the reporting person is a co-trustee or trustee and a beneficiary of these trusts.

Stakeholder Impact

• Shareholders: Received $21.00 cash per share and a contingent value right (CVR) for a potential additional $1.50 per share.
• Option Holders: Received cash for the in-the-money value of their options and one CVR per underlying share.

Next Steps

• Monitoring the achievement of milestones for the contingent value right (CVR) payment.

Key Dates

Keywords

Avadel Pharmaceuticals, AVDL, Alkermes, merger, acquisition, scheme of arrangement, Form 4, beneficial ownership, director, contingent value right, CVR, stock options, pharmaceutical M&A